ENABLE-2 partner Uppsala University publishes patent application


ENABLE-2 partner Uppsala University has published a first patent application on a series of compounds targeting the LpxH enzyme and showing highly potent in vivo activity. These compounds are active against wild-type bacterial cells, including carbapenem-resistant clinical isolates, and show very good efficacy in clearing infections in mouse models.

LpxH is an essential target in Gram-negative bacteria and there is no pre-existing resistance to this novel antibiotic class. 

ENABLE-2 News and media coverage

Last modified: 2022-05-19